Background: Plant-derived therapies are traditionally used as medicines, but they have generally not been studied with the same rigor as pharmaceutical agents. This review summarizes the use of plant-derived products for osteoarthritis. Methods: Sixty-three identified trials were summarized for pain, function, and safety outcomes using standardized mean differences (SMDs) and relative risks. Results: Plant-derived therapies are effective for treating pain compared to placebo, as assessed using visual analog scores and numerical rating scales (SMD, 1.08; 95% confidence interval [CI]: 0.72-1.44), or Western Ontario and McMaster University Osteoarthritis Index (WOMAC)/Knee injury and Osteoarthritis Outcome Score (KOOS) pain scales (SMD, 0.98; 95% CI: 0.62-1.35). Classes demonstrating overall efficacy in more than one trial for either visual analog scores or WOMAC pain included Boswellia serrata, capsaicin, and ginger; there was single-trial evidence of the efficacy of another nine agents. Plant-derived therapies have similar efficacy to an active comparator (SMD, 0.32; P=0.08; P=0.14). Therapies are also effective for functional outcomes compared to placebo (SMD, 0.92; P,0.001). However, significant heterogeneity remains for all pain and function outcomes, indicating that the results need to be interpreted with caution. Risk of adverse events was similar to placebo (relative risk =1.13; P=0.1), but reduced compared to an active comparator (relative risk, 0.75; P,0.001). Conclusion: Plant-derived therapies may be efficacious in treating osteoarthritic pain and functional limitations, and they appear to be safer than other active therapies. However, quality trials and long-term data are lacking, and the number of trials for each therapy is limited. Comparisons would be assisted by trial standardization.
Introduction
Osteoarthritis (OA) is the most common joint disorder and it predominantly affects the knees, hips, and hands of older adults. It is a leading cause of pain, functional limitations and disability worldwide, 1 with levels of disability among people with OA having increased globally by over 25% from 1990-2010. 2 Despite the large disease burden, OA etiology is poorly understood, and treatment remains palliative. Commonly involved joint structures include subchondral bone, ligaments, menisci, periarticular muscles, peripheral nerves, and synovium. 3, 4 OA is no longer considered to be a single disease entity, but a collection of heterogeneous pathologies that result in a common outcome. 5, 6 The lack of a common causal pathway has hampered the development of effective treatments for modifying the natural history of the disease. Most existing treatments focus on relieving pain and improving function, and there are few examples of therapies that modify disease. The pathogenesis of pain in OA is complex and multifactorial, involving local nociception, inflammatory mediators, and central sensitization. [5] [6] [7] [8] Treatment of osteoarthritic pain includes a wide range of therapies, from: nonpharmacological treatments (eg, education, weight reduction, physiotherapy); pain medications (eg, paracetamol, nonsteroidal anti-inflammatory drugs, opioids); nutraceuticals (eg, glucosamine, chondroitin sulfate); and surgical therapies (eg, joint replacement). Additionally, the effect sizes (ES) of existing treatments vary, but they are typically small to moderate 9 and fall short of the levels of pain relief desired by patients. 10 Medicinal plants form the basis of traditional medicinal systems around the world, and the number and type of botanically-based therapies and their mechanisms of action are similarly diverse. Given the limited efficacy of many existing treatments, there is considerable scope for alternative therapies, and plant-based therapies are well-placed to supplement this gap.
Additionally, controversy surrounding use of cyclooxygenase-2 inhibitors and heightened cardiovascular risk, [11] [12] [13] [14] highlights the importance of finding safer treatment options to minimize adverse side effects. 15 Botanical treatments may play a role in treatment of OA even if they are only moderately effective if they also have favorable safety profiles compared to alternatives (eg, nonsteroidal anti-inflammatory drugs). Additionally, given the high proportion of persons with OA using complementary and alternative medicines of various types, 16 ,17 assessment of treatment efficacy and the relative risk (RR) of side effects is warranted.
The efficacy and safety of plant-based therapies for OA have been the subject of several previous reviews. [18] [19] [20] [21] However, the number of studies trialing therapies is steadily increasing, necessitating more recent reviews; no previous reviews have summarized trials in such a way that efficacy and safety are directly comparable, either to placebo or to an active comparator.
Therefore, this review investigates the efficacy and safety of plant-derived products for the treatment of OA, as compared to placebo and active comparators, on OA pain and function.
Methods

Identification of clinical trials
Literature databases (PubMed and Embase) were searched for randomized controlled trials of botanical therapies as an intervention for pain or functional outcomes in OA, where the comparator was a placebo or an active comparator. The following keywords were used: "phytotherapy OR medicinal plants OR plant extract OR herbal"; "osteoarthritis" (both as a single phrase and as a topic) and "hip" or "knee" or "hand"; "randomized controlled trial [publication type]" or "controlled clinical trial [publication type]"; and "humans" that were published up to June 2013. This was supplemented by manually searching the bibliographies of relevant published reviews and papers.
Database searches identified a total of 144 studies: 92 in PubMed and 104 in Embase, and 52 in both. This yielded 58 studies after unsuitable trials were excluded. Supplemented papers included one notable plant-based treatment class, which did not appear in the original search (capsaicin) and an article using pine bark, which was not indexed under plant-based therapies. 22 
Inclusion/exclusion criteria
The included studies were randomized controlled trials of at least one plant-based therapy conducted with humans, where at least a subpopulation of adult patients had OA, as long as this subpopulation was presented separately. Studies were excluded if they were observational studies, not in English, where the botanical therapy was not the subject of the trial, where the botanical therapy was in both active and control medications (but no additional botanical therapy was used as an intervention), and when insufficient data were reported to extract ES (eg, where medians rather than means were reported). Topical therapies were included. Studies on animal populations and in participants with back pain or spinal OA were excluded. Studies were read by one reviewer (LLL).
Definition of plant-derived products
Treatments were included if they were any type of plantderived intervention (defined as any plant preparation, including whole, powder, extract, or standardized mixture), and they were excluded if there was any preparation of synthetic origin. These treatments could be used in any way, but they are typically ingested orally or applied topically on the skin (Table 1) .
Treatments could be compared to an inert substance (placebo) or an active comparator. Botanical therapies used in conjunction with other treatments or combined with a nonbotanical substance were also included if the effect of the nonherbal intervention was consistent among all groups and was quantifiable. Treatment arms were omitted if they were additional to active versus placebo or active versus active comparator comparisons. Plant-derived therapies for osteoarthritis
Data extraction and quality assessment
Data relating to treatment duration, demographic information, OA site, route, intervention(s), the patient-rated outcomes of pain and function, ES, and adverse events were extracted into predefined tables by one author (LLL). Methodological quality was assessed using The Cochrane Collaboration's tool for assessing risk of bias by one author (XJ). 23 Studies were assessed as having a low risk of bias, unclear risk of bias, or a high risk of bias. Included domains were: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective reporting; and other sources of bias (scoring for individual items is shown in Table 2 ). Scores were summed to create a risk of bias score (possible range: 0-14), with higher scores indicating a greater risk of bias. Studies were also scored as to whether or not they required participants to cease pain medications prior to trial entry (yes/no). Table 1 shows the 63 double-blind randomized controlled trials of therapies of botanical origin to treatment of pain in OA. 22, The 63 studies include eight case-crossover clinical trials. 41, 61, 64, 67, 68, 76, 81, 82 Treatment duration ranged from 1 week-1 year. Inclusion and exclusion criteria varied between trials, but patients were typically required to have at least moderate pain and either radiological evidence of OA or to be clinically diagnosed as having OA, or both. Where a study was defined as a case-crossover trial, data were extracted only up to the point of crossover, so that the data could be compared with those derived from parallel trials.
Identified trials
Outcome assessment
Pain outcomes included individual pain intensity scores assessed using a visual analog scale ([VAS], continuous data ranging from 0-100) or a numeric rating scale ([NRS]; integers), or a Likert scale (numbers representing descriptions, eg, "never", "sometimes", "often"), and data from the pain scales of pain and function questionnaires ( ). Data were used from total pain scores where possible.
Rasch analyses of the WOMAC pain subscale have previously suggested that it measures a combined function-pain construct. 88, 89 Function outcomes included the KOOS symptom score, 87 the WOMAC function score, 86 and the Lequesne's functional index. 90 Adverse events included the total number of patients with one or more adverse events.
Trials that did not have data for any of the above categories did not contribute data to this review.
Statistics
Data were analyzed using the "metan" command in Stata 12.1 (StataCorp LP, College Station, TX, USA). Statistical significance was set as a P-value #0.05 (two-tailed).
The main analyses were performed using a random effects model that generated an estimate of ES (standardized mean difference [SMD] ). This is calculated by dividing the mean difference between treatments by the standard deviation (SD) of the difference. It is, therefore, a number without units that can be used for cross-study comparisons. Clinically, ES =0.2 is considered small, ES =0.5 is moderate, and ES .0.8 is a large effect. 9 These were pooled using the method of DerSimonian and Laird. 91 Subgroup analyses were analyzed using a random effects model if there was significant heterogeneity and fixed effects model if there was not. Fixed effects models were weighted using the inverse of the variance of the difference in means. All estimates of heterogeneity were taken from the MantelHaenszel model. Associations between the risk of bias score and ES were assessed using the Spearman's rank correlation coefficients. Adverse event data were summarized using both fixed and random effects. The direction of the effect of KOOS outcome data was reversed to meaningfully pool it with WOMAC data.
A change in means was calculated using the final result minus the baseline result. Standard error or SD for the change in means was obtained from original papers where available. Where unavailable, the standard error of the difference was calculated using the following formula,
where baseline and follow-up are the first and last time points, and r is the correlation between standard errors, conservatively assumed to be 0.7. Adverse event data were assessed using RR.
Results
Summaries of the 63 included trials are presented in Table 1 . These studies encompass a wide range of botanical therapies administered orally, topically, and by other methods. Treatments were predominantly conducted on OA of the knee, but they also included OA of the hand and hip. Results are presented for pain outcomes (VAS, NRS pain scores, and WOMAC and KOOS pain scales), function, and adverse events data, and are presented separately by comparator (placebo or active control). Data were summarized by 
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Plant-derived therapies for osteoarthritis year of publication and compared using SMDs as compared to placebo or an active comparator. An active comparator is typically a nonsteroidal anti-inflammatory agent, but it also includes any other osteoarthritic therapy.
Efficacy
Pain efficacy compared to placebo 22, 52 ( Figures 1 and 2 ). For pain, as assessed by the VAS, NRS, and Likert pain scores (Figure 1 ), the SMDs (given using random effects) for subgroups are: comfrey, 1. 64 and stinging nettle (Urtica dioica) 76 did not reach statistical significance. These results are also summarized in Table 3 .
For WOMAC and KOOS pain scores (Figure 2 ), the SMD for Boswellia serrata extracts and blends is 4.21 (95% CI: 1.85-6.57; P,0.001), with considerable heterogeneity. All trials required patients to cease pain medications. Later trials had substantially smaller ES, though all are large. The SMD for ginger-based therapies is 0.28 (95% CI: 0.10-0.46; P=0.002), without significant heterogeneity. However, the two trials, not including massage, had much 
Pain efficacy compared to active comparator
For pain, as assessed by VAS, NRS, and Likert pain scores, the overall SMD was 0.32 (95% CI: -0.04 to 0.67; P=0.08), indicating no significant benefit for botanical therapies on pain scores (as assessed by VAS and NRS pain scales) when compared to an active comparator (Figure 3) , and -0.08 (95% CI: -0.42 to 0.25; P=0.6) for WOMAC/KOOS pain scores. There was significant heterogeneity between studies (I 2 =90.1%, P,0.001 [ Figure 3 ]; I 2 =85.9% [ Figure 4 ]) There was no association between the risk of bias and ES for either 58 Maheu 1998 79 Cisár 2008 Agents demonstrating significant benefit over placebo include UP446 (250 mg/day and 500 mg/day formulations), 28 E-OA-07 (extract of shyonak, ashwagandha, shunthi, guggal, chopchini, rasana, and shallaki), 34 passion fruit peel, 39 SKI306X (extract of Clematis mandshurica, Trichosanthes kirilowii, and Prunella vulgaris), 74 and NP 06-1 (Phellodendron amurense), but the effect was present only for overweight patients and absent in obese patients 44 (data not shown).
Compounds containing Urtica dioica demonstrated benefit in one study, 48 but not in another. 76 Studies investigating the effect of 4Jointz ® , 25 there is significant heterogeneity between studies (I 2 =92.7%; P,0.001). Botanical therapies that demonstrate efficacy when compared to an active comparator are olive oil 29 and UP446
28
(both low and high doses). Du huo ji sheng wan 62 and willow bark 63 favored the active comparator. There was no association between ES and risk of bias (ρ=0.2; P=0. 44 ). Figure 5 shows that the RR of one or more adverse events was not increased among patients receiving botanical therapies compared to placebo (RR =1.13; 95% CI: 0.98-1.31; P=0.10) using a random effects model, with significant heterogeneity (P=0.050), and I 2 of 28.0%. Ginger and capsaicin were associated with increase risk of adverse events: the RR for ginger is 1.40 (95% CI: 1.09-1.80, P=0.009), and the RR for capsaicin is 5.59 (95% CI 2.92-10.69; P,0.001). This is attributable to gastrointestinal events in the largest ginger trial 71 and a localized burning sensation at the site of application for capsaicin. No trials other than those using capsaicin demonstrated an increased risk of adverse events compared to placebo. Reporting was often inadequate, with underreporting of adverse events common, particularly for adverse events that the investigators considered as not related to the study drug. Figure 6 shows that the RR of one or more adverse events was reduced among patients receiving botanical therapies compared to an active comparator (RR =0.75; 95% CI: 0.65-0.85; P,0.001) using a fixed effects model, with no heterogeneity (P=0.4), and I 2 of 3.3%. Only one individual trial demonstrated reduced risk of adverse events compared to the active comparator; 77 where Harpadol (Harpagophytum procumbens) reduced the risk of adverse events when compared to diacerein 100 mg/day over 4 months of treatment. A reduction in adverse events was primarily found to be the reduction in gastrointestinal side effects when compared to nonsteroidal anti-inflammatory medications.
Safety
Discussion
This review compared the effects of plant-derived therapies from randomized controlled trials, when compared to placebo or an active comparator, on osteoarthritic pain and function. The efficacy of plant-derived therapies is superior to placebo and comparable to active comparators for treating 70 Pengkhum 2012 30 Widrig 2007 57 Madhu 2013 24 Chantre 2000 77 Usha 2006 Kuptniratsaikul 2011 45 Sontakke 2007 
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Plant-derived therapies for osteoarthritis osteoarthritic pain and functional limitations. Risk of one or more adverse events is not increased with the use of plantbased therapies when compared to placebo, but the risk is decreased by 25% when compared to an active comparator. Therefore, plant-derived therapies have a favorable risk profile compared to standard osteoarthritic therapies. We observed significant heterogeneity for both pain and functional outcomes. This is expected, as these plant-derived therapies contain a wide variety of active ingredients and, therefore, potentially therapeutically active molecules. 20 However, heterogeneity exists within classes, which is not explained by differences in the chemical components of treatments. The trials of ASUs 69, 75, 79, 80 have SMDs with a very wide range. The trial by Lequesne et al 69 is the longest at 12 months' duration, with others trialed over 3 months 75, 80 or 6 months' durations. 79 This may indicate that ASU is not efficacious over longer periods of time for osteoarthritic knee pain. Several trials of Boswellia serrata 36, 38, 54, 59, 60, 66, 68, 81 
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Laslett et al extremely large ES. All trials in this class required study participants to cease pain medications before the trials commenced, possibly increasing the likelihood of demonstrating an effect of the plant therapy. None of the trials in this class was classified as being at high risk of bias in any category, although the risk of bias was unclear in numerous domains in several trials.
Among the four included trials of topical capsaicin, 41, 78, 83, 84 all had high risk of bias in one subgroup, three had incomplete outcome data (attrition bias), and one exhibited allocation concealment. The use of capsaicin is associated with an increased risk of adverse events (RR =5.6), primarily a burning sensation at the site of application, which is of mild intensity and Figure 5 Safety of plant-derived therapies compared to placebo: incidence of one or more adverse events. Abbreviations: n, number of study participants; FNZG, Fufang Nanxing Zhitong Gao; SJG, Shangshi Jietong Gao; RR, relative risk; CI, confidence interval; AIF, antiinflammatory factor; TCM, traditional Chinese medicine; M-H, effect size for the risk ratio using a fixed effect model using the method of Mantel and Haenszel; D+L, effect size for the risk ratio using a random effects model using the method of DerSimonian and Laird. 
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Plant-derived therapies for osteoarthritis diminishes with continued use. 83, 92 However, this common adverse event makes allocation concealment of capsaicin trials challenging.
The ES (in SMDs) of many of the trials is very large, exceeding 1. While this is technically and methodologically possible, some of the exceedingly large ES are unexpectedly and implausibly large. Statistically significant correlations between study quality and ES have been reported in other settings, but we did not observe that in this review. Most studies included estimates of variation (either SD or standard errors) of baseline and follow-up measurements, but not change scores, with over 60% of studies not having SD or standard errors for change scores. Therefore, correlations between baseline and the last follow-up have been estimated conservatively at r=0.7. This underestimates the ES if the true correlation is larger than this and overestimates it if the true correlation is smaller. For example, the SMD for VAS/ NRS pain scores for the Boswellia class is 1.33 with the existing assumption (r=0.7), 2.03 (95% CI: 1.01-3.06) with a higher correlation (r=0.95), and 1.13 (95% CI: 0.67-1.59) with a lower correlation (r=0.5) -though botanical therapy is favored over placebo in all three scenarios. In these scenarios, SMD for VAS/NRS pain scores overall are 1.62 (95% CI: 1.10-2.14; r=0.95), 0.94 (95% CI: 0.62-1.26; r=0.5), and 0.86 (95% CI: 0.57-1.15; r=0.3). Correlations are also likely to vary between treatment, placebo, and active control groups and they may be different depending on the intervention studied. Overall, estimates in this review may be underestimates of efficacy if the correlation is greater than this and they may be overestimates if the correlation is less. Reporting of the SD or standard error of the mean of the change in outcomes is required for more precise pooling of study data in future reviews.
Many therapies are only trialed in one clinical trial, or in only one trial for an individual outcome. First, this suggests that additional studies are required to validate the findings, and second, this makes pooling therapies difficult or impossible. This is especially so when treatments are compared to an active comparator but this is more broadly applicable. Numerous studies were poorly described, with only 12 studies having a low risk of bias in all dimensions, and only a further 12 studies scored as having a risk of bias that was unclear in only one dimension. Conduct of the trial (or reporting of the conduct of the trial) in the remaining studies was unclear regarding the risk of bias in more than one domain, and 31% were at high risk of bias in one or more domains. Use of the Consolidated Standards of Reporting Trials statement for the reporting of new clinical trials will be a welcome development.
Conclusion
Plant-derived therapies may be efficacious in treating osteoarthritic pain and functional limitation when compared to placebo, and similarly effective when compared to active comparators. The safety profile is similar to placebo and better than active comparators. However, quality trials and 57 Teekachunhatean 2004 62 Kuptniratsaikul 2011 35 Biegert 2004 63 Jung 2004 65 Sampalis 2012 28 Pengkhum 2012 30 Sontakke 2007 59 Pavelka 2010 40 Kuptniratsaikul 2009 45 Chantre 2000 77 Sampalis 2012 28 Niempoog 2012 26 Drozdov 2012 27 Wu 2002 70 Medhi 2009 
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Laslett et al long-term data are lacking, and the number of trials for each therapy is limited. A comparison of efficacy would be assisted by trial standardization.
